Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Secnidazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 41Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lupin divests women’s health specialty business in US to Evofem for $84 million
    Lupin divests women’s health specialty business in US to Evofem for $84 million

    15 Jul 2024

    // MONEY CONTROL

    https://www.moneycontrol.com/news/business/companies/lupin-divests-womens-health-specialty-business-in-us-to-evofem-for-84-million-12769646.html

    MONEY CONTROL
    15 Jul 2024
    Share Share
    Lupin Divests US Women's Health Specialty Business To Evofem
    Lupin Divests US Women's Health Specialty Business To Evofem

    15 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lupin-divests-us-commercial-womens-health-specialty-business-to-evofem-including-solosec-302196783.html

    PR NEWSWIRE
    15 Jul 2024
    Share Share
    Lupin’s Solosec bags FDA approval for bacterial vaginosis and trichomoniasis
    Lupin’s Solosec bags FDA approval for bacterial vaginosis and trichomoniasis

    18 Feb 2022

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=145915&sid=2

    PHARMABIZ
    18 Feb 2022
    Share Share
    Lupin Signs Promotional Agreement with Exeltis on SOLOSEC
    Lupin Signs Promotional Agreement with Exeltis on SOLOSEC

    27 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/lupin-signs-promotional-agreement-with-exeltis-on-solosec-secnidazole-expanding-access-for-adult-women-suffering-with-bacterial-vaginosis-and-adults-with-trichomoniasis-301469860.html

    PRNEWSWIRE
    27 Jan 2022
    Share Share
    Lupin gets USFDA approval of sNDA for SOLOSEC (secnidazole)
    Lupin gets USFDA approval of sNDA for SOLOSEC (secnidazole)

    09 Jul 2021

    // EXPRESS PHARMA

    https://www.expresspharma.in/lupin-gets-usfda-approval-of-snda-for-solosec-secnidazole-to-treat-trichomoniasis/

    EXPRESS PHARMA
    09 Jul 2021
    Share Share
    Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC
    Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC

    01 Jul 2021

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lupin-announces-fda-approval-of-supplemental-new-drug-application-for-solosec-secnidazole-for-the-treatment-of-trichomoniasis-301324270.html

    PR NEWSWIRE
    01 Jul 2021
    Share Share